Skip to content
Disclosery

GREAT POINT PARTNERS LLC

Follow

13F filer, CIK 1281446, Greenwich, CT

GREAT POINT PARTNERS LLC reported $308,414,328 across 29 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-17. Its ten largest share positions make up 62.02% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001172661-26-001093

Period
2025-12-31
Reported value
$308M
Holdings
29
Top 10 weight
62.02%
New
12
Sold out
13

Largest buys vs the previous quarter

SecurityShares changeApprox. value
IRONnew+250,000$19.9M
RAPTnew+581,187$19.7M
VORnew+1,370,107$17.9M
KALVnew+685,632$11.1M
CTNMnew+800,000$9.14M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ASNDexited-75,000-$14.9M
ABVXexited-150,000-$12.7M
CYTKexited-150,000-$8.24M
XENEexited-200,000-$8.03M
IONSexited-80,000-$5.23M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001172661-26-001093, largest first. % of portfolio is the value over $308,414,328, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 304,000 shares; 2025Q4: 374,000 shares 374,000$28.2M9.15%+70,000Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,811,996 shares; 2025Q2: 2,000,000 shares; 2025Q3: 1,700,000 shares; 2025Q4: 1,750,000 shares 1,750,000$21.1M6.85%+50,000Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,263,672 shares; 2024Q4: 3,170,194 shares; 2025Q1: 3,170,194 shares; 2025Q2: 3,170,194 shares; 2025Q3: 3,815,930 shares; 2025Q4: 3,815,930 shares 3,815,930$20M6.48%0Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 250,000 shares 250,000$19.9M6.44%newTimeline
RAPTRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 581,187 shares 581,187$19.7M6.38%newTimeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 375,000 shares; 2025Q2: 262,176 shares; 2025Q3: 500,000 shares; 2025Q4: 750,000 shares 750,000$19.1M6.18%+250,000Timeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 225,000 shares; 2025Q4: 400,000 shares 400,000$18.5M6%+175,000Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,370,107 shares 1,370,107$17.9M5.81%newTimeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 275,000 shares; 2024Q4: 275,000 shares; 2025Q1: 275,000 shares; 2025Q2: not reported; 2025Q3: 265,803 shares; 2025Q4: 350,000 shares 350,000$14.4M4.68%+84,197Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 498,054 shares; 2025Q3: 632,599 shares; 2025Q4: 806,273 shares 806,273$12.4M4.03%+173,674Timeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,299,503 shares; 2024Q4: 1,787,003 shares; 2025Q1: 1,014,367 shares; 2025Q2: 323,170 shares; 2025Q3: not reported; 2025Q4: 685,632 shares 685,632$11.1M3.59%newTimeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 800,000 shares 800,000$9.14M2.96%newTimeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,200,000 shares; 2025Q4: 1,200,000 shares 1,200,000$9.06M2.94%0Timeline
FULCFULCRUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 800,000 shares 800,000$9.05M2.93%newTimeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 300,000 shares; 2025Q4: 210,732 shares 210,732$8.91M2.89%-89,268Timeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 300,000 shares; 2025Q1: 300,000 shares; 2025Q2: 300,000 shares; 2025Q3: 300,000 shares; 2025Q4: 300,000 shares 300,000$8.14M2.64%0Timeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,004,291 shares; 2024Q4: 442,761 shares; 2025Q1: 470,964 shares; 2025Q2: 485,859 shares; 2025Q3: 446,814 shares; 2025Q4: 350,000 shares 350,000$7.21M2.34%-96,814Timeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 300,000 shares 300,000$6.9M2.24%newTimeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,934,982 shares; 2024Q4: 4,683,711 shares; 2025Q1: 4,683,711 shares; 2025Q2: 4,683,711 shares; 2025Q3: 4,683,711 shares; 2025Q4: 4,683,711 shares 4,683,711$6.89M2.23%0Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 634,032 shares 634,032$6.56M2.13%newTimeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 325,000 shares 325,000$5.56M1.8%newTimeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 514,659 shares; 2024Q4: 228,803 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 183,330 shares; 2025Q4: 183,330 shares 183,330$5.56M1.8%0Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 808,032 shares 808,032$4.91M1.59%newTimeline
UNCYUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 796,558 shares; 2025Q3: 796,558 shares; 2025Q4: 796,558 shares 796,558$4.6M1.49%0Timeline
CLYMCLIMB BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 248,168 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 979,534 shares 979,534$3.92M1.27%newTimeline
SANASANA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 700,000 shares; 2025Q4: 700,000 shares 700,000$2.85M0.92%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 155,105 shares; 2025Q4: 82,800 shares 82,800$2.3M0.75%-72,305Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 124,666 shares 124,666$2.26M0.73%newTimeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 621,894 shares; 2025Q1: 833,042 shares; 2025Q2: 3,033,462 shares; 2025Q3: 2,451,809 shares; 2025Q4: 951,809 shares 951,809$2.25M0.73%-1,500,000Timeline

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ASNDASCENDIS PHARMA A/S75,000$14.9Mshares
ABVXABIVAX SA150,000$12.7Mshares
CYTKCYTOKINETICS INC150,000$8.24Mshares
XENEXENON PHARMACEUTICALS INC200,000$8.03Mshares
IONSIONIS PHARMACEUTICALS INC80,000$5.23Mshares
AKROAKERO THERAPEUTICS INC103,848$4.93Mshares
TSHATAYSHA GENE THERAPIES INC1,500,000$4.91Mshares
DBVTDBV TECHNOLOGIES S A378,594$3.79Mshares
LEGNLEGEND BIOTECH CORP113,460$3.7Mshares
ABSIABSCI CORPORATION796,438$2.42Mshares
HRMYHARMONY BIOSCIENCES HLDGS IN85,000$2.34Mcall
PLRXPLIANT THERAPEUTICS INC850,000$1.26Mshares
CAPRCAPRICOR THERAPEUTICS INC87,700$632Kput

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001172661-26-001093 base2026-02-17acceptance time not in the bulk data set